Latest news with #Akolkar
Business Insider
28-06-2025
- Business
- Business Insider
Nuvama Remains a Buy on Aurobindo Pharma Ltd (AUROPHARMA)
In a report released yesterday, Shrikant Akolkar from Nuvama maintained a Buy rating on Aurobindo Pharma Ltd (AUROPHARMA – Research Report), with a price target of INR1,460.00. The company's shares closed yesterday at INR1,121.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Akolkar is a 2-star analyst with an average return of -2.3% and a 0.00% success rate. Akolkar covers the Healthcare sector, focusing on stocks such as Aurobindo Pharma Ltd, Cipla Ltd, and Jubilant Pharmova Limited. Currently, the analyst consensus on Aurobindo Pharma Ltd is a Moderate Buy with an average price target of INR1,430.00. Based on Aurobindo Pharma Ltd's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of INR83.82 billion and a net profit of INR9.03 billion. In comparison, last year the company earned a revenue of INR75.8 billion and had a net profit of INR9.09 billion
Business Insider
28-06-2025
- Business
- Business Insider
Nuvama Sticks to Their Buy Rating for Jubilant Pharmova Limited (JUBLPHARMA)
In a report released yesterday, Shrikant Akolkar from Nuvama maintained a Buy rating on Jubilant Pharmova Limited (JUBLPHARMA – Research Report), with a price target of INR1,385.00. The company's shares closed yesterday at INR1,173.90. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Akolkar is a 2-star analyst with an average return of -2.3% and a 0.00% success rate. Akolkar covers the Healthcare sector, focusing on stocks such as Aurobindo Pharma Ltd, Cipla Ltd, and Jubilant Pharmova Limited. The word on The Street in general, suggests a Hold analyst consensus rating for Jubilant Pharmova Limited. Based on Jubilant Pharmova Limited's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of INR19.29 billion and a net profit of INR1.54 billion. In comparison, last year the company earned a revenue of INR17.59 billion and had a GAAP net loss of INR586 million
Business Insider
28-06-2025
- Business
- Business Insider
Nuvama Keeps Their Buy Rating on Lupin Limited (LUPIN)
In a report released yesterday, Shrikant Akolkar from Nuvama maintained a Buy rating on Lupin Limited (LUPIN – Research Report), with a price target of INR2,530.00. The company's shares closed yesterday at INR1,935.20. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Akolkar is a 2-star analyst with an average return of -2.3% and a 0.00% success rate. Akolkar covers the Healthcare sector, focusing on stocks such as Aurobindo Pharma Ltd, Cipla Ltd, and Jubilant Pharmova Limited. Currently, the analyst consensus on Lupin Limited is a Strong Buy with an average price target of INR2,328.75. Based on Lupin Limited's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of INR55.62 billion and a net profit of INR7.73 billion. In comparison, last year the company earned a revenue of INR48.95 billion and had a net profit of INR3.59 billion
Business Insider
28-06-2025
- Business
- Business Insider
Nuvama Sticks to Their Hold Rating for Cipla Ltd (CIPLA)
In a report released yesterday, Shrikant Akolkar from Nuvama maintained a Hold rating on Cipla Ltd (CIPLA – Research Report), with a price target of INR1,620.00. The company's shares closed yesterday at INR1,502.40. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Akolkar is a 2-star analyst with an average return of -2.3% and a 0.00% success rate. Akolkar covers the Healthcare sector, focusing on stocks such as Aurobindo Pharma Ltd, Cipla Ltd, and Jubilant Pharmova Limited. The word on The Street in general, suggests a Hold analyst consensus rating for Cipla Ltd with a INR1,665.00 average price target. The company has a one-year high of INR1,702.00 and a one-year low of INR1,310.05. Currently, Cipla Ltd has an average volume of 56.27K.
